Moderna vaccinates first participant in phase 2 trial of Omicron-specific booster as study finds that antibodies fall 6-fold over 6 months

Moderna announced Wednesday that the first participant has been dosed in the company's Phase 2 clinical trial of a coronavirus vaccine booster shot that is specific to the Omicron variant.

Read More